A RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER

Trial Profile

A RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Alectinib (Primary) ; Crizotinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALEX
  • Sponsors Roche
  • Most Recent Events

    • 03 Aug 2017 According to a Genentech media release, the US FDA has accepted the company's sNDA and granted Priority Review for Alecensa (alectinib) as an initial (first-line) treatment for people with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic NSCLC as detected by an FDA-approved test. The FDA will make a decision on approval by November 30, 2017. This sNDA submission for Alecensa is based on results from the Phase III ALEX and Phase III J-ALEX studies.
    • 06 Jun 2017 Primary results (data cut-off; 9 Feb 2017) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 According to a Genentech media release, results from this trial will be published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top